Literature DB >> 27053230

EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease.

.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27053230     DOI： 10.1007/s00125-016-3902-y

Source DB:  PubMed          Journal:  Diabetologia        ISSN： 0012-186X            Impact factor:   10.122


× No keyword cloud information.
  148 in total

Review 1.  Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease.

Authors:  Giovanni Targher; Christopher P Day; Enzo Bonora
Journal:  N Engl J Med       Date:  2010-09-30       Impact factor: 91.245

2.  Liver fat is increased in type 2 diabetic patients and underestimated by serum alanine aminotransferase compared with equally obese nondiabetic subjects.

Authors:  Anna Kotronen; Leena Juurinen; Antti Hakkarainen; Jukka Westerbacka; Anja Cornér; Robert Bergholm; Hannele Yki-Järvinen
Journal:  Diabetes Care       Date:  2007-10-12       Impact factor: 19.112

Review 3.  Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: a systematic review.

Authors:  Christian Thoma; Christopher P Day; Michael I Trenell
Journal:  J Hepatol       Date:  2011-07-01       Impact factor: 25.083

4.  Effect of lifetime alcohol consumption on the histological severity of non-alcoholic fatty liver disease.

Authors:  Hellan K Kwon; Joel K Greenson; Hari S Conjeevaram
Journal:  Liver Int       Date:  2013-06-28       Impact factor: 5.828

5.  Bariatric surgery versus intensive medical therapy for diabetes--3-year outcomes.

Authors:  Philip R Schauer; Deepak L Bhatt; John P Kirwan; Kathy Wolski; Stacy A Brethauer; Sankar D Navaneethan; Ali Aminian; Claire E Pothier; Esther S H Kim; Steven E Nissen; Sangeeta R Kashyap
Journal:  N Engl J Med       Date:  2014-03-31       Impact factor: 91.245

6.  Modest alcohol consumption is associated with decreased prevalence of steatohepatitis in patients with non-alcoholic fatty liver disease (NAFLD).

Authors:  Winston Dunn; Arun J Sanyal; Elizabeth M Brunt; Aynur Unalp-Arida; Michael Donohue; Arthur J McCullough; Jeffrey B Schwimmer
Journal:  J Hepatol       Date:  2012-04-17       Impact factor: 25.083

7.  Effect of a 12-month intensive lifestyle intervention on hepatic steatosis in adults with type 2 diabetes.

Authors:  Mariana Lazo; Steven F Solga; Alena Horska; Susanne Bonekamp; Anna Mae Diehl; Frederick L Brancati; Lynne E Wagenknecht; F Xavier Pi-Sunyer; Steven E Kahn; Jeanne M Clark
Journal:  Diabetes Care       Date:  2010-07-27       Impact factor: 19.112

8.  Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes.

Authors:  Mirja Tiikkainen; Anna-Maija Häkkinen; Elena Korsheninnikova; Tuulikki Nyman; Sari Mäkimattila; Hannele Yki-Järvinen
Journal:  Diabetes       Date:  2004-08       Impact factor: 9.461

9.  Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease.

Authors:  Sunder Mudaliar; Robert R Henry; Arun J Sanyal; Linda Morrow; Hanns-Ulrich Marschall; Mark Kipnes; Luciano Adorini; Cathi I Sciacca; Paul Clopton; Erin Castelloe; Paul Dillon; Mark Pruzanski; David Shapiro
Journal:  Gastroenterology       Date:  2013-05-30       Impact factor: 22.682

Review 10.  Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis.

Authors:  Giovanni Musso; Roberto Gambino; James H Tabibian; Mattias Ekstedt; Stergios Kechagias; Masahide Hamaguchi; Rolf Hultcrantz; Hannes Hagström; Seung Kew Yoon; Phunchai Charatcharoenwitthaya; Jacob George; Francisco Barrera; Svanhildur Hafliðadóttir; Einar Stefan Björnsson; Matthew J Armstrong; Laurence J Hopkins; Xin Gao; Sven Francque; An Verrijken; Yusuf Yilmaz; Keith D Lindor; Michael Charlton; Robin Haring; Markus M Lerch; Rainer Rettig; Henry Völzke; Seungho Ryu; Guolin Li; Linda L Wong; Mariana Machado; Helena Cortez-Pinto; Kohichiroh Yasui; Maurizio Cassader
Journal:  PLoS Med       Date:  2014-07-22       Impact factor: 11.069
View more
  121 in total

Review 1.  NAFLD/NASH in patients with type 2 diabetes and related treatment options.

Authors:  M G Radaelli; F Martucci; S Perra; S Accornero; G Castoldi; G Lattuada; G Manzoni; G Perseghin
Journal:  J Endocrinol Invest       Date:  2017-11-30       Impact factor: 4.256

2.  EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease: is universal screening appropriate?

Authors:  Christopher D Byrne; Giovanni Targher
Journal:  Diabetologia       Date:  2016-04-07       Impact factor: 10.122

3.  Use of HOMA-IR to diagnose non-alcoholic fatty liver disease: a population-based and inter-laboratory study.

Authors:  Elina Isokuortti; You Zhou; Markku Peltonen; Elisabetta Bugianesi; Karine Clement; Dominique Bonnefont-Rousselot; Jean-Marc Lacorte; Amalia Gastaldelli; Detlef Schuppan; Jörn M Schattenberg; Antti Hakkarainen; Nina Lundbom; Pekka Jousilahti; Satu Männistö; Sirkka Keinänen-Kiukaanniemi; Juha Saltevo; Quentin M Anstee; Hannele Yki-Järvinen
Journal:  Diabetologia       Date:  2017-06-29       Impact factor: 10.122

4.  Weight Reduction and Pioglitazone are Cost-Effective for the Treatment of Non-Alcoholic Fatty Liver Disease in Thailand.

Authors:  Bunchai Chongmelaxme; Pochamana Phisalprapa; Ratree Sawangjit; Piyameth Dilokthornsakul; Nathorn Chaiyakunapruk
Journal:  Pharmacoeconomics       Date:  2019-02       Impact factor: 4.981

Review 5.  Non-Alcoholic Fatty Liver Disease: Cause or Effect of Metabolic Syndrome.

Authors:  Christoph Grander; Felix Grabherr; Alexander R Moschen; Herbert Tilg
Journal:  Visc Med       Date:  2016-09-16

6.  The PNPLA3 rs738409 C>G variant interacts with changes in body weight over time to aggravate liver steatosis, but reduces the risk of incident type 2 diabetes.

Authors:  Ming-Feng Xia; Huan-Dong Lin; Ling-Yan Chen; Li Wu; Hui Ma; Qian Li; Qiqige Aleteng; Yu Hu; Wan-Yuan He; Jian Gao; Hua Bian; Xiao-Ying Li; Xin Gao
Journal:  Diabetologia       Date:  2019-01-23       Impact factor: 10.122

7.  Observed changes in brown, white, hepatic and pancreatic fat after bariatric surgery: Evaluation with MRI.

Authors:  Steve C N Hui; Simon K H Wong; Qiyong Ai; David K W Yeung; Enders K W Ng; Winnie C W Chu
Journal:  Eur Radiol       Date:  2018-07-30       Impact factor: 5.315

8.  EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease: disease mongering or call to action?

Authors:  Elisabetta Bugianesi
Journal:  Diabetologia       Date:  2016-04-07       Impact factor: 10.122

9.  The liver in focus.

Authors:  Michael Roden
Journal:  Diabetologia       Date:  2016-04-07       Impact factor: 10.122

Review 10.  [New aspects of nonalcoholic steatohepatitis].

Authors:  N Stefan
Journal:  Internist (Berl)       Date:  2019-02       Impact factor: 0.743
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.